Drug Trial Radar · NCT06011291
A Study of SYH2051 Monotherapy in Advanced Solid Tumors or in Combination With Radiotherapy in Locally Advanced Head and Neck Cancer
Last checked: Nov 20, 2026Latest source record: Oct 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
73
Planned (sponsor's estimate)
Start
Aug 15, 2023
Primary completion
Dec 31, 2024
Study completion Aug 31, 2025
Sponsor
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter, dose-escalation phase I study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor efficacy of SYH2051 in patients with advanced solid tumors or in combination with radiotherapy (RT) in patients with locally advanced head and neck cancer.
Conditions
- Solid Tumors
- Head and Neck Cancer
Interventions
SYH2051 tabletsDrug
Arm A: Five dose levels will be administered sequentially. Arm B and C: Concurrently administered with RT, and 2 weeks adjuvant treatment after RT.
Intensity-Modulated Radiation Therapy (IMRT)Radiation
Radical or adjuvant radiotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicities (DLTs)Time frame: 31 days for Arm A and 11 weeks for Arm B
- Incidence of adverse events (AEs) and serious adverse events (SAEs)Time frame: 2 years
- Maximum tolerated dose (MTD)(if any) or maximum administrated dose (MAD)Time frame: up to 1 year
- Recommended phase 2 dose (RP2D) of SYH2051 in combination with RTTime frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Trials Information Group
Shijiazhuang, Hebei, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.